Interim report January-June 2008 Key events during the period • Net revenues amounted to MSEK 80.2 (15.2) • A loss after tax of MSEK 90.5 (loss: 94.5) was reported • Earnings per share amounted to a loss of SEK -4.19 (loss: 6.80) • The exclusive world rights to two Orexo pharmaceuticals, Sublinox™ (OX22) and OX NLA, were licensed to Meda AB. • Rapinyl™/Abstral was approved for registration in Europe by the EMEA's Committee for Medicinal Products for Human Use (CHMP). • Cash flow from continuing operations was MSEK -42,8 (-97,5) Second quarter of 2008 • Net revenue amounted to MSEK 56.2 (8.8) • The loss after tax was MSEK 28.3 (loss: 56.6) • Earnings per share amounted to a loss of SEK 1.31 (loss: 4.06) • Cash flow from continuing operations was MSEK 45,7 (-48,6) Key events after the closing date • After the initial evaluation, the registration application for SublinoxTM (OX22) was accepted as complete for final evaluation by the Food and Drug Administration (FDA) in the US. • Orexo expanded the licensing agreement with ProStrakan for Rapinyl™/Abstral and changed partners in the US.
Interim report January-June 2008
| Source: Orexo AB